RTTR vs. KPRX, MNPR, PPBT, RDHL, AVTX, PIRS, IMNN, HUGE, EDSA, and ELAB
Should you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Kiora Pharmaceuticals (KPRX), Monopar Therapeutics (MNPR), Purple Biotech (PPBT), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Imunon (IMNN), FSD Pharma (HUGE), Edesa Biotech (EDSA), and Elevai Labs (ELAB). These companies are all part of the "medical" sector.
Ritter Pharmaceuticals (NASDAQ:RTTR) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
Ritter Pharmaceuticals has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
Ritter Pharmaceuticals received 290 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. Likewise, 70.23% of users gave Ritter Pharmaceuticals an outperform vote while only 66.67% of users gave Kiora Pharmaceuticals an outperform vote.
In the previous week, Kiora Pharmaceuticals had 7 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 7 mentions for Kiora Pharmaceuticals and 0 mentions for Ritter Pharmaceuticals. Ritter Pharmaceuticals' average media sentiment score of 0.00 beat Kiora Pharmaceuticals' score of 0.00 indicating that Ritter Pharmaceuticals is being referred to more favorably in the media.
0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Kiora Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 1,339.74%. Given Kiora Pharmaceuticals' higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Ritter Pharmaceuticals.
Ritter Pharmaceuticals' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.
Summary
Ritter Pharmaceuticals and Kiora Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Ritter Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ritter Pharmaceuticals Competitors List
Related Companies and Tools
